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Aims: Models are needed to quantify the economic implications of obesity in rela-
tion to health outcomes and health‐related quality of life. This report presents the
structure of the Core Obesity Model (COM) and compare its predictions with the
UK clinical practice data.
Materials and methods: The COM is a Markov, closed‐cohort model, which expands
on earlier obesity models by including prediabetes as a risk factor for type 2 dia-
betes (T2D), and sleep apnea and cancer as health outcomes. Selected outcomes
predicted by the COM were compared with observed event rates from the Clinical
Practice Research Datalink‐Hospital Episode Statistics (CPRD‐HES) study. The
importance of baseline prediabetes prevalence, a factor not taken into account in
previous economic models of obesity, was tested in a scenario analysis using data
from the 2011 Health Survey of England.
Results: Cardiovascular (CV) event rates predicted by the COM were well matched
with those in the CPRD‐HES study (7.8–8.5 per 1000 patient‐years across BMI
groups) in both base case and scenario analyses (8.0–9.4 and 8.6–9.9, respectively).
Rates of T2D were underpredicted in the base case (1.0–7.6 vs. 2.1–22.7) but
increased to match those observed in CPRD‐HES for some BMI groups when a pro-
spectively collected prediabetes prevalence was used (2.7–13.1). Mortality rates in
the CPRD‐HES were consistently higher than the COM predictions, especially in
higher BMI groups.
Conclusions: The COM predicts the occurrence of CV events and T2D with a good
degree of accuracy, particularly when prediabetes is included in the model, indi-
cating the importance of considering this risk factor in economic models of obesity.
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1 | INTRODUCTION
The high prevalence and chronic nature of obesity are com-
pounded by the large number of related complications.1 There
is extensive evidence of a link between body mass index (BMI)
and type 2 diabetes (T2D), as well as cardiovascular disease
(CVD), including both chronic complications, such as hyperten-
sion and coronary heart disease, and acute events such as
myocardial infarction (MI) and stroke.1,2 Furthermore, obesity is
associated with other complications across multiple organ sys-
tems, including sleep apnea3 and osteoarthritis, and is also
implicated in the development of some types of cancer.4 These
complications incur a substantial proportion of obesity‐related
healthcare costs.5–7
Health economic models of obesity are used to assess the cost‐
effectiveness of weight management interventions, driving health-
care decision‐making and allocation of resources. To do this, such
models estimate the risk of BMI‐related complications, the impact on
health‐related quality of life (HRQoL), and the associated economic
costs.8 Obesity models set in the UK healthcare system, assessing the
long‐term impact of T2D and CVD, and also incorporating mortality,
have previously been developed, principally for use in economic
predictions. These models have been used to assess the cost‐utility of
orlistat9 and compare the cost‐effectiveness of orlistat, sibutramine,
and rimonabant,8 and to assess the cost‐effectiveness of the Light-
erLife weight management program10 and the Weight Action Pro-
gram11 However, these previous models can be refined and improved
upon; given the multifactorial nature of overweight and obesity and
the range of associated complications, the incorporation of additional
comorbidities and risk factors offers the potential to improve the
accuracy of predictions. Furthermore, models must be fit for purpose
and interpretable by key stakeholders. This need for transparency
and accuracy in model development has informed published best
practice guidelines by the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) and the Society for Medical
Decision Making (SMDM).12,13
This report presents the development and structure of the novel
Core Obesity Model (COM; version 8.0). The COM was designed to
encompass a broader range of complications than previous models
and includes the impact of sleep apnea, knee replacement as a result
of osteoarthritis, postmenopausal breast cancer, postmenopausal
endometrial cancer, and colorectal cancer. The model also in-
corporates the impact of prediabetes, which is known to be associ-
ated with increased all‐cause mortality, as well as a higher risk of
T2D and CVD.14
Furthermore, the results of an analysis comparing model pre-
dictions with observed rates of obesity‐related complications in the
UK clinical practice data are presented, to demonstrate the func-
tionality of the COM and assess the impact of baseline glycemic
status on its predictions while highlighting areas for further refine-
ment of the model.
2 | MATERIALS AND METHODS
2.1 | Core Obesity Model overview
2.1.1 | Model structure
The COM is a Markov, closed‐cohort model. In a Markov model,
the disease being studied is divided into distinct and mutually
exclusive states (health states) and transition probabilities are
assigned to represent patients moving between these states over
discrete time periods called “Markov cycles”. By applying these
transitions in the model and attaching estimates of resource use
and health consequences to the states, followed by running the
model over a large number of cycles, it is possible to estimate
the longitudinal costs and outcomes associated with the disease.
The health states are chosen to represent clinically and econom-
ically important events in the disease process. The states are
mutually exclusive: a patient can only be in one state at a time
and cannot transition to a less severe health state.15 The COM
comprises 18 single or combined obesity‐related health states
(Figure 1), intended to reflect the disease course and impact of
effective weight management interventions for individuals who are
currently living with BMI above 25 kg/m2.16 The model was
originally developed in Microsoft Excel 2013. The structure in-
corporates key findings from previous obesity models and has
been refined by reviewing the relevant literature and incorpo-
rating expert clinical feedback to establish face validity.13 A
cohort state‐transition model was chosen to avoid the need for
extensive code and computational intensiveness associated with
microsimulation models17 while maximizing transparency and user‐
friendliness.
Patients enter the model in a defined baseline health state
(i.e., no comorbidity, prediabetes, or T2D) and at each model cycle
can either remain in the same state or transition to another state.
The time horizon of the model is 40 years, chosen to represent a
lifetime time horizon for most of the cohort commencing weight
management and entering the model. Transition probabilities are
based on risk equations or risk tables for each obesity‐related
complication from published landmark epidemiological studies and
linking surrogate endpoints, such as BMI, systolic blood pressure
(SBP), lipids, glycemic status, and for those with T2D, glycated
hemoglobin (HbA1c) to “hard” clinical outcomes, such as CVD and
diabetes. These surrogate endpoints are risk factors for obesity‐
related complications and typical endpoints in relevant clinical
trials.
The effect of weight management interventions on transition
probabilities between health states is incorporated via the observed
effect that these interventions have on BMI and cardiometabolic risk
factors (Table 1). Third‐party payer, patient and societal costs, and
HRQoL data associated with interventions and health states are also
incorporated into the model.
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TAB L E 1 Definition of treatment effects on physiological parameters included in the Core Obesity Model
Surrogate outcomes Treatment effect included in the model
BMI, kg/m2 BMI percentage change from baseline (note: percentage weight change in kg is equal to
percentage BMI change)
SBP, mmHg SBP absolute change from baseline
HDL cholesterol, mg/dL HDL cholesterol absolute change from baseline
Total cholesterol, mg/dL Total cholesterol absolute change from baseline
HbA1c, %, in diabetes HbA1c percentage‐point change from baseline
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F I GUR E 1 Structure of the Core Obesity Model. This model schematic was previously published as part of a manuscript describing the
validation of the Core Obesity Model30 and is reproduced here in accordance with the Creative Commons Attribution‐Non‐Commercial 4.0
International License (http://creativecommons.org/licenses/by‐nc/4.0/) and with the permission of the copyright holders (authors). ACS, acute
coronary syndrome; BMI, body mass index; HbA1c, glycated hemoglobin; SBP, systolic blood pressure; T2D, type 2 diabetes
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2.1.2 | Baseline characteristics
The baseline characteristics of a hypothetical patient cohort (e.g., age,
sex, and cardio‐metabolic risk factors: BMI, SBP, lipids, and HbA1c
level [for those with T2D]) are defined at model entry (Table 2), and
are classified as either static (do not change over time) or dynamic
(change over time).
2.1.3 | Health states in the model
The obesity‐related complications included in the model health states
are T2D, CVD (consisting of acute coronary syndrome [ACS] and
stroke), cancer (postmenopausal endometrial, postmenopausal
breast, and colorectal), and death. Additionally, in any given health
state, patients can undergo knee replacement surgery because of
debilitating osteoarthritis, or undergo bariatric surgery. Sleep apnea
was applied at baseline and throughout the time horizon to a pro-
portion of the cohort, and not considered a separate health state,
because it can co‐exist with other complications and its onset is not
thought to have an impact on mortality or other transition proba-
bilities (Figure 1).18
Complications were selected for inclusion in the model because:
(1) there is either strong or moderate evidence for their association
with obesity (Table 3), based on a comprehensive report from the
World Health Organization,19 and also referenced in subsequent
reports on the burden of obesity‐related conditions;20,21 (2) they
have a considerable impact on HRQoL, life expectancy and/or
healthcare resources and costs; and (3) they are known to be affected
by weight management interventions.19





Age years Dynamic Defined at baseline and increasing by 1 unit each year spent alive in the
cohort
BMI kg/m2 Dynamic Defined at baseline; changes as a result of treatment; when treatment is
stopped weight is regained after a defined period (catch‐up period)
and afterwards has a natural progression (increase) until a
predefined age
Height cm Static Defined at baseline, does not change
SBP mmHg Dynamic Defined at baseline, changes as a result of treatment (if decreased due
to treatment, catch up after treatment stop is assumed)
Total cholesterol mg/dl Dynamic Defined at baseline, changes as a result of treatment (if decreased due
to treatment, catch up after treatment stop is assumed)
HDL cholesterol mg/dl Dynamic Defined at baseline, changes as a result of treatment (if increased due to
treatment, catch up after treatment stop is assumed)
HbA1c in cohort with type 2 diabetes % Dynamic Defined at baseline, changes as a result of treatment. When the entire
cohort has diabetes, following treatment stop and catch‐up period,
HbA1c increases over time based on natural progression in diabetes
population
Type 2 diabetes duration in cohort with type
2 diabetes
years Dynamic Defined at baseline and increasing by 1 each year spent alive in the
cohort
Triglyceride level ‐ Static Defined at baseline, does not change
Proportion with triglyceride level ≥150 mg/
dl
% Static Defined at baseline, does not change
Proportion smokers % Static Defined at baseline, does not change
Proportion women % Static Defined at baseline, changes with mortality
Proportion Mexican Americans (for US
cohort only)
% Static Defined at baseline, does not change
Proportion receiving lipid‐lowering drugs % Static Defined at baseline, does not change
Proportion receiving antihypertensive
medication
% Dynamic Defined at baseline, may change as a result of treatment (if decreased
owing to treatment, catch up after treatment stop is assumed)
Age at menopause years Static Defined at baseline, does not change
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; SBP, systolic blood pressure.
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TAB L E 3 Summary of obesity‐related complications included in the Core Obesity Model
Complications with strong evidence of association with obesity Complications with moderate evidence of association with obesity
Type 2 diabetes Knee replacement
Acute coronary syndrome (including myocardial infarction) Colorectal cancer
Stroke (including transient ischemic attack) Postmenopausal endometrial cancer
Sleep apnea Postmenopausal breast cancer
20 22 24 26 28 30 32 34 36 38 40 42 4420 22 24 26 28 30 32 34 36 38 40 42 44
20
00
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F I GUR E 2 Risk prediction estimates used in the Core Obesity Model. BMI, body mass index; CV, cardiovascular; NDR, National Diabetes
Register; NGT, normal glucose tolerance; T2D, type 2 diabetes; UKPDS, UK Prospective Diabetes Study
2.1.4 | Transition probabilities and risk equations
Risk equations for transition probabilities were selected using
epidemiological studies identified in a systematic literature review
(unpublished) conducted by the School of Health and Related
Research (Sheffield, United Kingdom) and supplemented with a
pragmatic search.
2.1.5 | Type 2 diabetes
The two alternative risk equations for the development of
T2D in individuals with either no comorbidity or prediabetes
were sourced from the QDiabetes study and the Framingham
Offspring Study (Figure 2A,B, respectively);22,23 consequently, risk
equations developed in both UK and US populations were used
in the model. The QDiabetes‐2018 algorithm predicts the 10‐year
risk of T2D in patients aged 25–84 years as a function of BMI
and other associated risk factors; the model has been vali-
dated externally22 and is recommended by the National Institute
for Health and Care Excellence (NICE) for T2D risk identification
in the United Kingdom.24 Compared with the Framingham
Offspring Study, the QDiabetes study included a longer prediction
range (10 vs. 8 years), wider age range (25–84 years vs. 25–
64 years) and higher maximum BMI (40 vs. 30 kg/m2).22,23
To reflect the higher risk of T2D in individuals with prediabetes
the HbA1c parameter was set to equal 42 mmol/mol (equivalent
to 6%).
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2.1.6 | Cardiovascular disease and other obesity‐
related complications
In the COM, CVD is defined as ACS (includes MI and unstable angina)
or stroke (includes transient ischemic attack [TIA]). Different equa-
tions can be used to estimate the risk of CVD as either a first‐time or
recurrent event. Furthermore, because T2D was included as a risk
factor for CVD in all risk‐prediction models, it is possible to differ-
entiate between CVD risk in patients with T2D and risk in those with
normal glucose tolerance.
The risk of CVD as a first‐time event may be predicted in the
model via four studies. For individuals with normal glucose tolerance,
risk of CVD as a first‐time event may be predicted using the QRISK3
study or the Framingham Heart Study (Figure 2C).25,26 For cohorts
from Europe, the estimate from the QRISK3 study is preferred and
for those from the United States, the Framingham Heart Study is
preferred. Neither of these studies quantifies the risk of CVD in in-
dividuals with prediabetes. Therefore, the risk of CVD as a first‐time
event was assumed to be the same for individuals with normal
glucose tolerance and for those with prediabetes. For individuals with
T2D, the QRISK3 study, the United Kingdom Prospective Diabetes
Study (UKPDS) outcomes model 2 or the Swedish National Diabetes
Registry (Figure 2D) may be used.27,28
The risk for CVD as a recurrent event was based on estimates
from the Framingham Recurring Coronary Heart Disease Study for
individuals with normal glucose tolerance and for those with T2D;
the UKPDS can be used as an alternative for individuals with
T2D.28,29 To reflect the increased risk of recurrent cardiovascular
(CV) events in individuals with impaired glucose tolerance and a
history of CV events,14 the risk of CVD as a recurrent event for in-
dividuals with prediabetes was assumed to be the same as for those
with T2D.
Risk estimates for other events and transitions to other health
states are summarized in Table 4. These risk equations were selected
following identification of relevant studies in the systematic review.
Appropriate studies for inclusion were those that focused on relevant
populations; were relevant to the countries or regions of interest;
reported on the association between BMI, other risk factors relevant
to the model, where available, and the outcomes of interest; and were
judged to be of high quality. High‐quality studies were considered to
be those with appropriate design and modeling, and use of large
patient populations to develop and validate risk equations.
2.1.7 | Mortality
General population mortality (defined as age‐ and sex‐specific all‐
cause mortality) was included in the model based on country‐specific
life tables. Changes to the probability of mortality associated with MI,
unstable angina, stroke, knee replacement, and certain cancers were
made via adjustments to the general population mortality applied in
the COM (Table 5).
2.2 | CPRD‐HES study and Core Obesity Model
comparative analysis
A recently published external validation of the COM showed that it
reliably predicts the occurrence of obesity‐related complications.41
The aim of this analysis was to assess how baseline glycemic status
impacts model predictions using event rates sourced from a large
analysis of merged patient data from the Clinical Practice Research
Datalink (CPRD), Hospital Episode Statistics (HES), and the Office for
National Statistics examining associations between BMI and obesity‐
related complications in a cohort of more than 2.9 million individuals
followed up for a median of 11.4 years.42
2.2.1 | Baseline data and model parameters
Individuals in the CPRD‐HES study were stratified into five groups
based on conventional BMI cut‐offs, with normal weight (BMI
18.5–24.9 kg/m2) as the reference group. The baseline demographic
and disease characteristics of these groups (Table 6) were used to
populate the model.
The COM was used to simulate the incidence of CV events (MI/
unstable angina and stroke/TIA) and T2D, as well as all‐cause mor-
tality. Analyses were conducted over a 10‐year time horizon in a
cohort of 100 individuals and translated into event rates per 1000
patient‐years by division with the model's projected undiscounted
life expectancy.
Longitudinal data reflecting changes to BMI over time were not
investigated in the CPRD‐HES study; consequently, in this analysis,
BMI was assumed to remain constant over time. No weight man-
agement intervention effects were considered in these analyses.
2.2.2 | Calculation of event rates
Cox‐adjusted event rates for each BMI group were calculated by
multiplying the crude event rates in the normal weight group by the
TAB L E 4 Summary of sources used to derive risk estimates for
health state transitions in the Core Obesity Model
Complication Risk estimate source(s)
Sleep apnea Young et al. 200218
Knee replacement Wendelboe et al. 200330
Colorectal cancer Adams et al. 200731
Schlesinger et al. 201532
Postmenopausal endometrial cancer Renehan et al. 200833
Yang et al. 201234
Postmenopausal breast cancer Ahn et al. 200735
Renehan et al. 200833
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Cox‐proportional hazard ratios (HRs; Table 7) for events of interest
in each BMI group. The CPRD‐HES analyses were adjusted for age,
sex and smoking status. In the COM, the baseline characteristics of
the reference BMI group were kept, and the mean BMI was changed
per each of the simulated BMI groups according to the mean BMI
reported in the CPRD‐HES study.




in year of onset
Estimate source(s) Estimate applied in years post onseta Estimate source(s)Female Male
Myocardial infarction 30.00% 32.00% BHF36 RR: 1.30 Johansson et al.37
Unstable angina 30.00% 32.00% BHF36 RR: 1.30 Johansson et al.37
Stroke 24.70% 17.10% BHF36 RR: 2.00 Brammas et al.38
Knee replacement 0.30% Singh et al.39 and CRUK40 NA NA
Cancer: Probability: 4.31% CRUK40
Colon 30.11% CRUK40
Postmenopausal endometrial 10.54% CRUK40
Postmenopausal breast 4.08% CRUK40
Abbreviations: BHF, British Heart Foundation; CRUK, Cancer Research UK; NA, not applicable; RR, relative risk.
aRelative risks are applied to the age and sex‐specific annual probabilities of mortality.
TAB L E 6 Baseline characteristics of the CPRD‐HES BMI groups
BMI group Normal 18.5–24.9 kg/m2 25.0–29.9 kg/m2 30–34.9 kg/m2 35–39.9 kg/m2 40–44.9 kg/m2
N 1,099,106 1,074,953 507,425 176,237 67,231
Mean age, years (SD) 48.5 (19.2) 53.1 (16.9) 52.1 (15.9) 49.3 (15.4) 47.4 (14.6)
Mean BMI, kg/m2 (SD) 22.5 (1.7) 27.3 (1.4) 32.1 (1.4) 37.0 (1.4) 42.3 (1.5)
Mean height, m (SD) 1.68 (0.09) 1.69 (0.10) 1.68 (0.10) 1.66 (0.10) 1.65 (0.10)
Smoking, % ever smoked 49.3 50.2 50.6 48.8 47.3
Sex, % women 64.6 49.7 53.1 62.9 70.9
Individuals on antihypertension medication, % 14.7 22.3 26.1 26.7 28.5
Individuals on lipid‐lowering medication, % 8.3 13.9 15.7 14.6 14.9
Mean SBP, mmHg (SD) 128.2 (71.4) 135.4 (73.8) 138.3 (54.2) 139.4 (56.7) 140.0 (57.7)
Mean total cholesterol, mg/dl (SD) 203.7 (41.5) 207.8 (42.0) 208.0 (42.2) 206.2 (41.7) 201.2 (40.9)
Mean HDL, mg/dl (SD) 61.0 (18.1) 53.9 (16.5) 50.4 (15.3) 48.8 (14.4) 47.5 (14.2)
Mean HbA1c, % (SD) 7.5 (1.6) 7.6 (1.5) 7.7 (1.5) 7.8 (1.5) 7.8 (1.6)
Mean triglycerides, mg/dl (SD) 118.9 (69.0) 152.2 (87.9) 175.0 (98.1) 180.1 (99.4) 177.0 (94.6)
Individuals with triglyceride levels ≥150 mg/dl, % 22.4 40.0 51.7 54.3 53.8
Individuals without pre‐T2D or T2Da,b, % 95.3 90.2 85.5 82.5 78.8
Individuals with pre‐T2D with laboratory values, % 2.0 4.1 5.9 6.9 6.7
Individuals with T2D, % 2.7 5.7 8.6 10.6 14.5
T2D duration, years (SD) 5.9 (6.9) 5.0 (6.1) 4.5 (5.6) 4.3 (5.4) 4.1 (5.1)
Abbreviations: BMI, body mass index; CPRD‐HES, Clinical Practice Research Datalink‐Hospital Episode Statistics; HbA1c, glycated hemoglobin; HDL,
high‐density lipoprotein; SBP, systolic blood pressure; SD, standard deviation; T2D, type 2 diabetes.
aCalculated as 100% minus the proportions of individuals with pre‐T2D or T2D.
bIn scenario analyses that adjusted prediabetes prevalence to real‐world values, distribution at baseline was modified to 25.9% prediabetes, 2.7% T2D
and 71.4% nonprediabetes and non‐T2D.
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2.2.3 | Scenario analysis with altered baseline
prediabetes prevalence
Laboratory test data used to derive prediabetes rates in CPRD were
available for only a small proportion of the individuals in the data-
base. Therefore, the prediabetes rates of 2.0%–6.9% across BMI
groups in the CPRD‐HES study (Table 6) were considered likely to be
an underestimate of rates in the general population, particularly
when contrasted with the 2011 Health Survey of England (HSE),
which reported rates of 25.9% in individuals with a BMI of 25 kg/m2
or less, 37.6% in those with a BMI of 25.0–29.9 kg/m2 and 47.9% in
those with a BMI of 30 kg/m2 or above.43
To examine the impact of altering baseline prediabetes preva-
lence, a scenario analysis was conducted in which the rate of pre-
diabetes for individuals of normal weight reported in the HSE was
used for the reference group in the model. Baseline T2D prevalence
was not altered in this analysis.
2.2.4 | Assessment of concordance
Model concordance was assessed by plotting the predicted outcomes
(Y‐axis) against the observed study endpoints (X‐axis). To quantify
overprediction and underprediction, an ordinary least‐squares linear
regression line (OLS LRL) was fitted to the observed data, with an
intercept of zero. Slope values below 1.0 suggest underprediction and
values above 1.0 suggest overprediction. Coefficients of determina-
tion (R2) were calculated for all results to quantify linear correlation
between the observed and predicted outcomes in cases where OLS
LRL was close to the IL.
3 | RESULTS
3.1 | Comparison of predictions with CPRD‐HES
study data
Table 8 shows the observed and predicted values for all outcomes in
the base case and scenario analyses. The incidence of CV events was
slightly overpredicted by the model (8.0–9.4 per 1000 patient‐years
across BMI groups) compared with observed values (7.8–8.5 across
groups), as indicated by an OLS LRL slope of 1.091 (Table 9). Similar
results were obtained as part of the scenario analysis where baseline
prediabetes prevalence was adjusted (Table 8).
Incidence of T2D was strongly linked to BMI in the CPRD‐HES
study, with rates increasing exponentially from 2.1 in the normal
weight group to 22.7 in those with a BMI of 40.0–45.0 kg/m2. A
similar pattern was apparent in the model predictions; however, T2D
incidence was generally underpredicted by the COM (OLS LRL slope
of 0.368 [Table 9]), especially in the highest BMI group (7.6 vs. 22.7).
When baseline prediabetes prevalence was increased to the level
observed in the HSE survey, predicted T2D rates were consistent
with observed values in the lower BMI groups (18.5–24.9 and 25.0–
29.9 kg/m2; Table 8); however, event rates were still underpredicted
in the other BMI groups (overall OLS LRL slope: 0.655; Table 9). The
underprediction was highest in the 40.0–45.0 kg/m2 group (13.1 vs.
22.7), indicating that underestimation of prediabetes in the CPRD‐
HES study contributed to the low predicted T2D rates in base case
analyses.
Observed all‐cause mortality event rates showed a gradual
increase across the BMI groups, with a rate of 8.9 for those with
BMI between 25.0 and 29.9 kg/m2, rising to 14.0 for those with BMI
40.0–45.0 kg/m2. However, the predicted rates remained relatively
constant across groups (4.9–5.2), indicating that mortality rate pre-
dictions by the COM may be insensitive to changes in BMI. This
underprediction was confirmed by linear regression analysis (OLS
LRL slope: 0.445; Table 9); however, the negative R2 value obtained
from this analysis (−26.840; Table 9) limited the ability to fully
interpret the result. All‐cause mortality predictions were consistent
in the scenario analysis (Table 8), suggesting that prediabetes prev-
alence did not significantly affect mortality during the modeled time
horizon.
3.2 | Comparison of predictions generated by
different versions of the Core Obesity Model
As part of the development of the COM, a previous version (6.1) was
subjected to an extensive validation process, according to best
practice guidelines.13 Results from a comparison between the current
(8.0) and validated (6.1) versions of the COM (Table 8) showed that
the validated version produced similar trends across BMI groups to
those predicted by the current version, but that predicted event
rates were generally slightly lower.
TAB L E 7 Cox proportional hazard ratios used for Core Obesity Model predictions
BMI BMI BMI BMI BMI
18.5–24.9 kg/m2 25–29.9 kg/m2 30–34.9 kg/m2 35–39.9 kg/m2 40–45 kg/m2
Unstable angina/myocardial infarction, HR (95% CI) 1.0 (reference) 1.03 (1.02–1.04) 1.11 (1.09–1.12) 1.14 (1.12–1.17) 1.18 (1.14–1.23)
Stroke/transient ischemic attack, HR (95% CI) 1.0 (reference) 0.92 (0.91–0.94) 0.94 (0.92–0.95) 0.98 (0.95–1.00) 1.02 (0.98–1.06)
Type 2 diabetes, HR (95% CI) 1.0 (reference) 2.30 (2.27–2.34) 4.73 (4.65–4.80) 7.81 (7.67–7.96) 10.8 (10.5–11.0)
All‐cause mortality, HR (95% CI) 1.0 (reference) 0.77 (0.76–0.77) 0.81 (0.80–0.82) 0.95 (0.94–0.97) 1.21 (1.18–1.24)
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio.
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4 | DISCUSSION
Economic models can be used to extrapolate the long‐term impacts
of a disease and estimate the relative benefits of different treatment
strategies. In conjunction with shorter‐term data provided by clinical
trials and observational studies, such projections are relevant to cli-
nicians, payers, and policy‐makers, particularly in the case of a
common, chronic condition such as obesity. Best‐practice guidance
highlights the need for transparency and validation to ensure that the
outputs of economic models can be interpreted with confidence by all
stakeholders.13 The aim of this study was to present the structure
and components of the COM in a transparent manner and provide a
single‐study example of its predictive ability.
The COM incorporates a broad range of obesity‐related health
states, allowing for the presence of single and multiple comorbidities,
and including complications both strongly and moderately related to
obesity. When deriving data to develop risk equations for these
complications, multiple relevant studies were considered, and those
that were most appropriate based on study population and setting
were selected. In their final appraisal determination for liraglutide,
TAB L E 8 Observed event rates from the CPRD‐HES study versus those predicted by the Core Obesity Model (versions 8.0 and 6.1)
Incidence, crude event rates/1000 patient‐years
BMI BMI BMI BMI BMI
18.5–24.9 kg/m2 25–29.9 kg/m2 30–34.9 kg/m2 35–39.9 kg/m2 40–45 kg/m2
Cardiovascular events, total
CPRD‐HES study, observed event rates 7.8 7.6 7.9 8.2 8.5
Core Obesity Model (version 8.0), predicted
Base case 8.0 8.3 8.7 9.2 9.4
Scenario analysis 8.3 8.6 9.1 9.7 9.9
Core Obesity Model (version 6.1), base case 6.0 6.2 6.6 7.0 7.1
Unstable angina or myocardial infarction
CPRD‐HES study, observed event rates 3.4 3.5 3.8 3.9 4.0
Core Obesity Model (version 8.0), predicted
Base case 6.0 6.3 6.6 6.9 7.1
Scenario analysis 6.2 6.5 6.9 7.3 7.5
Core Obesity Model (version 6.1), base case 4.5 4.7 4.9 5.2 5.3
Stroke or transient ischemic attack
CPRD‐HES study, observed 4.4 4.1 4.1 4.3 4.5
Core Obesity Model (version 8.0), predicted
Base case 2.0 2.1 2.2 2.3 2.3
Scenario analysis 2.0 2.1 2.3 2.4 2.5
Core Obesity Model (version 6.1), base case 1.5 1.6 1.7 1.8 1.8
Type 2 diabetes
CPRD‐HES study, observed 2.1 4.8 9.9 16.4 22.7
Core Obesity Model (version 8.0), predicted
Base case 1.0 2.2 4.2 6.6 7.6
Scenario analysis 2.7 4.8 8.0 11.6 13.1
Core Obesity Model (version 6.1), base case 1.1 2.3 4.2 6.5 7.5
All‐cause mortality
CPRD‐HES study, observed 11.6 8.9 9.4 11.0 14.0
Core Obesity Model (version 8.0), predicted
Base case 4.8 4.9 5.0 5.1 5.2
Scenario analysis 4.9 5.0 5.1 5.3 5.3
Core Obesity Model (version 6.1), base case 3.8 3.8 3.9 4.0 4.0
Abbreviations: BMI, body mass index; CPRD‐HES, Clinical Practice Research Datalink‐Hospital Episode Statistics.
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NICE judged that the model health states and transitions are suitable
for decision‐making.44 The COM also improves on previously devel-
oped models via the inclusion of a greater range of obesity‐related
complications, as well as incorporating the effects of baseline pre-
diabetes. The comparative analysis, in which adjustment of predia-
betes at baseline strongly influenced the prediction of T2D in the
model, demonstrates the importance of including this factor in
models of obesity. The relevance of prediabetes as a baseline factor is
supported by data indicating that individuals with this condition have
a 33%–66% risk of developing T2D within 3–6 years, as well as an
elevated risk of CVD compared with the general population.45
Predicted rates of CV events in the COM were well matched
with those observed in the CPRD‐HES study in both base‐case and
scenario analyses; however, overprediction of unstable angina/MI
rates and underprediction of stroke/TIA rates highlighted the role
that repartitioning can play during predictions of composite end-
points. All‐cause mortality event rate predictions were lower than
observed, which demonstrates the continuing refinement required
for economic models, including the potential for the addition of
further obesity‐related complications, such as chronic kidney disease,
as well as highlighting the incomplete understanding of the rela-
tionship between BMI and mortality. In the CPRD‐HES study, as in
several previous analyses,46–50 mortality was higher in individuals
with a BMI of 18.5–24.9 kg/m2 than in those with a BMI of 25.0–29.9
or 30.0–34.9 kg/m2. This may be partly attributable to unintentional,
pre‐diagnostic weight loss in individuals at high risk of death,
meaning that they are represented disproportionately in the lowest
BMI group; however, further research is required to understand the
contribution of BMI and other demographic and disease risk factors
to mortality. Notably, all patients entered the COM free of CVD;
however, this was not the case for patients in the CPRD‐HES study.
It must also be noted that mortality rates in the CPRD‐HES study
(index period: January 2000–December 2010) are higher than those
reported in several more recent studies. The 11.6%–14.0% mortality
across BMI groups in this data set contrasts with rates of 7.1% in a
study conducted by the Global BMI Mortality Collaboration,48 8.0%
in a 2018 study using CPRD data,47 and 3.9%51 and 4.0%,50
respectively, in studies published in 2019 using data from the UK
Biobank. This pattern is supported by the findings of a study that
examined mortality in five survey periods from 1986 to 2009, which
concluded that mortality is decreasing over time.52 Such trends may
be attributable, in part, to improvements in the management of
obesity‐related diseases during more recent decades. Therefore, the
fact that mortality estimates generated by the COM are low
compared with the rates observed in the CPRD‐HES data set may be
partly explained by the lower general population mortality informing
the non‐disease‐specific mortality in the COM (based on 2019
England and Wales general population mortality statistics published
by the Office of National Statistics), in line with the observed trend in
decreasing population mortality over the past decade.
The results of this single‐study comparison should also be
considered in the context of the published COM external validation
publication,41 which provides a more robust analysis of prediction
accuracy against a larger number of studies. It should also be noted
that when comparing the cost‐effectiveness of weight management
interventions, any misprediction of mortality or other factors applies
equally to both treatments being assessed, minimizing the risk of
bias. Furthermore, the ISPOR/SMDM guidelines do not quantify the
desired level of accuracy for the predictions made by models and
emphasize that such quantification would not be feasible or useful,
stating that “it is not possible to specify criteria that a model must
meet to be declared ‘valid’, as if validity were a property of the model
that applies to all of its applications and uses for all time.”12,13
Taken together, the comparisons of observed and predicted values
performed here provide further insight into the results of the previ-
ously reported external validation41 and highlight the importance of
baseline prediabetes prevalence. This analysis also indicates areas for
further improvement and refinement in the COM. Adjustments to the
COM are ongoing, in line with identification of new evidence; however,
the present study provides an example of the model's functionality at
this point in time, based on currently available published studies.
Furthermore, the trends in the predictions generated by the present
version of the COM (well‐matched predictions for CV events and for
T2D in the normal and overweight BMI groups and underprediction of
mortality across BMI groups) were consistent with a previous, exten-
sively validated, version of the COM.41
Predictive models and the economic analyses performed by them
are necessarily limited by the quality and scope of the data available.
For example, in the COM, some of the studies used to derive risk
estimates did not include BMI as an independent risk factor28 or did
not estimate the impact of BMI above a certain threshold.22,23,26
Therefore, the COM may underpredict disease risk for individuals
with a BMI greater than 40 kg/m2; this is reflected in the predicted
T2D incidence in these analyses, which was lower than observed
values in the highest BMI group. Furthermore, the COM is intended
to reflect clinical practice as accurately as possible; however, epide-
miological and database studies cannot capture all factors that affect
obesity and disease risk. Adherence to and persistence with
TAB L E 9 Linear regression analysis of observed event rates
versus those predicted by the Core Obesity Model
Outcome OLS LRL slope R2
Cardiovascular events (total)
Base case 1.091 0.750
Scenario analysis 1.141 0.719
Type 2 diabetes
Base case 0.368 0.954
Scenario analysis 0.655 0.862
All‐cause mortality
Base case 0.445 −26.840
Scenario analysis 0.455 −22.090
Abbreviations: OLS LRL, ordinary least‐squares linear regression line;
R2, coefficient of determination.
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medication, as well as demographic characteristics and medical his-
tory, which may constitute important risk factors, are unlikely to be
recorded fully in these databases. For example, socioeconomic status
is implicated in a considerable proportion of obesity53 but is not
captured in CPRD or similar retrospective data sources. Finally,
outcomes relating to CVD risk equations were subject to some as-
sumptions as a result of the source material available: the risk of CVD
as a first‐time event was assumed to be the same for individuals with
normal glucose tolerance and for those with prediabetes, and once an
individual developed prediabetes, their risk of CVD as a recurrent
event was the same as for those with T2D.
The COM improves on previous economic models of obesity8–11
due to the inclusion of additional health states and baseline charac-
teristics. The results of this study show that in the context of the UK
clinical practice, the COM can predict rates of CV events across BMI
groups and T2D in certain BMI groups, both of which are strongly
linked to obesity. Further adjustment to the model prediction of
mortality rates, especially at higher BMI levels, will improve and
refine its overall ability to estimate the occurrence and health
economic burden of obesity‐related complications, providing a
valuable tool to support healthcare decision‐making.
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